Compounded T4/T3 Combination Therapy: What Patients and Clinicians Need to Know

What Is Compounded T4/T3 Combination Therapy?

Compounded T4/T3 therapy combines pharmaceutical-grade levothyroxine (T4) and liothyronine (T3) into a single preparation made by a licensed 503A or 503B compounding pharmacy. The result is a dose ratio that cannot be achieved with any single FDA-approved product currently on the market. Physicians prescribe it most often when patients remain symptomatic on standard levothyroxine despite normal TSH values.

The healthy human thyroid secretes both hormones directly into circulation. About 80% of circulating T3 comes from peripheral conversion of T4 by deiodinase enzymes, but the gland contributes roughly 20% of daily T3 output on its own [1]. Patients with total thyroidectomy or severe autoimmune destruction (Hashimoto thyroiditis) may lose that direct T3 source entirely. For those individuals, relying solely on peripheral conversion of levothyroxine may not restore T3 to the levels a functioning gland would have maintained [2].

Compounding allows a pharmacist to prepare, for example, a capsule containing 75 mcg levothyroxine and 10 mcg liothyronine, or a slow-release liothyronine bead alongside standard T4, in a ratio the prescribing physician specifies. That flexibility is the core clinical argument for compounding over simply writing two separate commercial prescriptions.

How Compounded T4/T3 Differs from Commercial Alternatives

Four commercial options exist for thyroid hormone replacement, and each has a fixed limitation that compounding can address.

Levothyroxine (Synthroid, generic) supplies T4 only. It is the most prescribed thyroid medication in the United States, with more than 100 million prescriptions filled annually [3]. It works well for the majority of patients, but a 2018 JAMA Internal Medicine study of 49,427 levothyroxine users found that 5 to 10% continued to report fatigue and quality-of-life impairment despite biochemically normal TSH [4]. Tirosint, a gel-cap or liquid levothyroxine formulation, eliminates the fillers that can impair absorption in patients with celiac disease or lactose intolerance, but it is still T4 only [5].

Cytomel (liothyronine, synthetic T3) provides immediate-release T3. Because T3 has a half-life of roughly 19 hours versus levothyroxine's 7 days, Cytomel produces a sharp peak within 2 to 4 hours of ingestion and then falls. That peak can cause palpitations, anxiety, or elevated heart rate, which is why many endocrinologists split the daily dose into two administrations [6]. Compounded slow-release T3 blunts this peak. A 2017 pharmacokinetic study in Thyroid (N=36) confirmed that a sustained-release liothyronine preparation produced a significantly flatter T3 curve than immediate-release liothyronine at the same total dose [7].

Armour Thyroid and other desiccated thyroid extracts (DTEs) contain both T4 and T3 derived from porcine thyroid glands. The T4:T3 ratio in Armour Thyroid is approximately 4:1 by weight, which delivers proportionally more T3 than the human thyroid produces relative to T4 [8]. Patients who convert T4 well may find that ratio supraphysiologic in T3. Armour Thyroid, NP Thyroid, and Nature-Throid have also faced recurring supply issues and FDA scrutiny. In 2023, the FDA issued warning letters to manufacturers of unapproved animal-derived thyroid drugs, creating significant market uncertainty for patients on DTE [9].

Compounded T4/T3 sidesteps the DTE supply problem and lets the physician set a human-physiologic ratio, typically 13:1 to 20:1 T4:T3 by weight, rather than accepting the fixed 4:1 in Armour Thyroid.

The Clinical Evidence for Combination Therapy

The evidence base is real, though still debated at the guideline level. Here is what the key studies show.

Bunevicius 1999 (NEJM): The study that launched modern interest in combination therapy enrolled 33 hypothyroid patients and crossed them over between T4 monotherapy and a regimen that replaced 50 mcg of T4 with 12.5 mcg T3. On nearly all neuropsychological tests and mood scales, patients performed better on the combination. Seventeen of 33 preferred the combination regimen [10]. The trial was small, but it was published in the New England Journal of Medicine and is still cited in every subsequent guideline.

Saravanan 2005 (JCEM): A larger randomized crossover trial (N=697) in the Journal of Clinical Endocrinology and Metabolism found no statistically significant difference in quality of life between T4 monotherapy and T4+T3 combination across the full group [11]. However, subgroup analysis suggested patients with a specific DIO2 polymorphism (rs225014) responded better to combination therapy, a finding that has been replicated in subsequent pharmacogenomic work.

Idrees 2020 (Thyroid): A meta-analysis of 26 randomized controlled trials found that combination T4/T3 therapy was associated with improved patient preference and mood scores, but no consistent advantage on standard thyroid function tests [12].

DIO2 polymorphism data: Approximately 12 to 16% of the population carries the Thr92Ala variant in the type 2 deiodinase gene [13]. Carriers convert T4 to T3 less efficiently in the brain and pituitary. For these patients, T4 monotherapy may sustain normal serum T3 while leaving brain T3 relatively low. A 2019 study in Thyroid (N=552) found that Thr92Ala carriers reported significantly worse psychological well-being on T4 monotherapy compared with non-carriers [14]. Genetic testing for DIO2 variants is available but not yet standard of care.

The American Thyroid Association 2014 guidelines state: "We recommend against the routine use of combination T4 and T3 therapy," while explicitly allowing it as an option for patients who "feel unwell" on T4 monotherapy after "other causes of symptoms have been excluded" [15]. The European Thyroid Association 2012 guidelines take a similar position, noting that "a trial of LT4 plus LT3 combination treatment could be considered as an experimental approach in compliant LT4-treated hypothyroid patients" [16].

Dosing Rationale for Compounded T4/T3

Getting the T4:T3 ratio right matters clinically. The thyroid of a healthy adult secretes approximately 94 to 110 mcg of T4 and 6 to 8 mcg of T3 per day [1]. A physiologic replacement target, therefore, sits at roughly a 13:1 to 16:1 T4:T3 weight ratio.

Most endocrinologists prescribing compounded combination therapy start by reducing the existing T4 dose by 25 to 50 mcg and adding 5 to 10 mcg of compounded slow-release liothyronine. That substitution keeps total thyroid hormone load stable while introducing T3 [17]. From there, dose titration follows TSH and free T3 levels at 6-week intervals.

A practical example: a patient stable on levothyroxine 125 mcg/day might transition to a compounded capsule containing levothyroxine 100 mcg plus slow-release liothyronine 7.5 mcg, with a TSH recheck at 6 weeks. Free T4 and free T3 should both fall within the reference range before considering further adjustment.

Overreplacement with T3 carries real risk. Sustained supraphysiologic T3 is associated with atrial fibrillation, reduced bone mineral density, and left ventricular hypertrophy [18]. The ATA guidelines note that free T3 values above the upper limit of normal should prompt dose reduction regardless of how the patient feels subjectively [15].

Who Is a Candidate for Compounded T4/T3?

Not every hypothyroid patient needs compounding. The evidence supports considering it in specific clinical scenarios.

Patients who have had total thyroidectomy lose the direct T3 contribution of the gland permanently. A 2020 study in the Journal of Clinical Endocrinology and Metabolism (N=287 post-thyroidectomy patients) found that serum T3 remained significantly lower than in matched controls despite normal TSH on levothyroxine monotherapy [19]. That persistent T3 deficit is the strongest physiologic argument for combination therapy in this group.

Patients with confirmed Hashimoto thyroiditis and near-total thyroid destruction occupy a similar position. When residual thyroid tissue is minimal, peripheral conversion of T4 must carry the entire T3 burden, and individual variation in deiodinase activity is substantial [13].

Patients with documented DIO2 Thr92Ala homozygosity and persistent neurocognitive symptoms on adequate T4 monotherapy represent a third group where combination therapy has a specific mechanistic rationale [14].

Patients who simply prefer a trial of combination therapy after failing T4 alone, and who have no contraindications (atrial fibrillation history, severe osteoporosis, significant cardiac disease), may also be reasonable candidates after a thorough discussion of evidence and limitations [15].

Compounded T4/T3 vs. Two Separate Prescriptions

Some physicians write separate prescriptions for levothyroxine and liothyronine (Cytomel or generic) rather than using a compounding pharmacy. Both approaches deliver T4 and T3, but they are not identical.

A single compounded capsule improves adherence because the patient takes one pill instead of two, potentially at different times of day. Slow-release compounded T3 reduces peak T3 concentrations, which matters for patients sensitive to T3 surges. A 2017 pharmacokinetic study in Thyroid confirmed that slow-release liothyronine maintained T3 within the physiologic range throughout the dosing interval, while the same dose of immediate-release liothyronine produced a Cmax approximately 40% higher than the physiologic peak [7].

The compounding route does carry regulatory considerations. Compounded drugs are not FDA-approved and have not undergone the bioequivalence testing required of generic drugs [20]. Potency can vary between compounding pharmacies. Patients and prescribers should use a PCAB-accredited 503A pharmacy or an FDA-registered 503B outsourcing facility to minimize quality risk.

Cost is also a factor. Commercial generic levothyroxine runs roughly $4, 15 per month at most pharmacies. Generic liothyronine (Cytomel generic) adds $15, 40 per month. Compounded combination capsules typically run $30, 80 per month depending on dose and pharmacy, which may not be covered by standard insurance formularies.

Monitoring and Safety on Combination Therapy

Thyroid function testing on combination regimens requires a slightly different approach than T4 monotherapy monitoring.

TSH remains the primary marker. Target range on combination therapy is generally 0.5, 2.5 mIU/L per ATA guidelines, the same as for T4 monotherapy [15]. However, because T3 directly suppresses pituitary TSH secretion, free T3 must be checked alongside TSH to avoid inadvertent T3 overreplacement with a falsely normal-appearing TSH.

Free T4 is expected to run somewhat lower than on T4 monotherapy alone, because the T4 dose is usually reduced when T3 is added. A free T4 in the lower half of the reference range is acceptable if free T3 is mid-range and the patient is asymptomatic [17].

Bone mineral density monitoring is warranted annually in postmenopausal women on any thyroid hormone regimen that keeps TSH at or below the lower limit of normal. A 2015 meta-analysis in JAMA Internal Medicine (N=70,298) found that subclinical hyperthyroidism (TSH <0.45 mIU/L) was associated with a 1.52-fold increased hip fracture risk [21]. That risk applies to combination therapy as much as to T4 monotherapy.

Cardiac monitoring, specifically a baseline electrocardiogram in patients over 50 or those with cardiovascular risk factors, is prudent before initiating or significantly increasing T3 dose. Persistent tachycardia, new atrial ectopy, or palpitations after a dose change should prompt a dose reduction and cardiology referral if they do not resolve within 2 weeks [18].

Practical Steps to Starting Compounded T4/T3

The process from decision to first dose typically takes 2 to 4 weeks and involves several structured steps.

First, a full thyroid panel (TSH, free T4, free T3, anti-TPO antibodies) and a complete metabolic profile establish a baseline. If symptoms include fatigue and weight changes, ruling out iron deficiency, vitamin D insufficiency, and adrenal dysfunction before attributing everything to thyroid hormone conversion is standard practice.

Second, the prescriber selects a T4:T3 ratio and sends the prescription to a qualified compounding pharmacy. A common starting formula: the patient's current T4 dose minus 25 mcg, combined with 5 mcg slow-release liothyronine. Patients currently on Tirosint gel caps who switch to a compounded formula should allow 4 to 6 weeks for the new preparation to reach steady state before drawing labs.

Third, labs are rechecked at 6 weeks. If TSH is suppressed below 0.5 mIU/L or free T3 is above the upper limit of the reference range, the T3 component is reduced by 2.5 to 5 mcg before any further increase [15]. If TSH remains above 2.5 mIU/L and symptoms persist, a modest increase in the T4 component (12.5 to 25 mcg) is more conservative than raising T3.

Fourth, once stable, labs are monitored every 6 to 12 months. Annual bone density scans and an annual resting heart rate review (targeting 60, 80 bpm) are added to the monitoring schedule for patients over 50 [18].

The Armour Thyroid Supply Problem and Why Compounding Fills the Gap

Armour Thyroid (Forest/AbbVie) and competing desiccated thyroid products have faced repeated supply disruptions. Nature-Throid and WP Thyroid were voluntarily recalled in 2020. NP Thyroid experienced a recall in 2022 for sub-potency. The FDA's 2023 enforcement letters to DTE manufacturers, flagging their products as new drugs lacking approved new drug applications, added regulatory pressure that has not fully resolved [9].

Patients who relied on Armour Thyroid for years and found it effective face a real problem: no commercially available T4/T3 combination product has FDA approval in the United States. Compounded T4/T3 does not solve the regulatory question, but it does provide a stable, pharmacy-controlled alternative with a specifiable ratio and a quality paper trail from an accredited facility.

For patients transitioning from Armour Thyroid to compounded T4/T3, a rough conversion uses the fact that one grain (60 mg) of Armour Thyroid contains approximately 38 mcg T4 and 9 mcg T3 [8]. A patient on two grains (76 mcg T4 / 18 mcg T3) might be transitioned to a compounded preparation of 75 mcg T4 plus 10 mcg slow-release T3. Labs are checked 6 weeks post-transition.

Frequently Asked Questions